JSK Therapeutics Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
JSK Therapeutics General Information
Description
Developer of anti-cancer therapeutics designed to reduce pain and suffering by using chemistry against cancer. The company's therapeutics offer nitric oxide (NO)-generating compounds of the arylated diazeniumdiolate class and also develop initiatives for the treatment of acute myeloid leukemia and multiple myeloma, enabling doctors to treat and improve cancer patients' lives with fewer side effects.
Contact Information
Website
www.jskthera.comCorporate Office
- 47 West 200 South
- Suite 101
- Salt Lake City, UT 84101
- United States
Corporate Office
- 47 West 200 South
- Suite 101
- Salt Lake City, UT 84101
- United States
JSK Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 11. Later Stage VC | 30-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 10. Grant | 01-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 9. Later Stage VC | 11-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 21-Sep-2017 | Completed | Pre-Clinical Trials | |||
| 7. Grant | 01-Jan-2014 | Completed | Startup | |||
| 6. Grant | 01-Jan-2012 | Completed | Startup | |||
| 5. Grant | 01-Jan-2010 | Completed | Startup | |||
| 4. Seed Round | 07-Nov-2008 | $325K | $325K | Completed | Startup | |
| 3. Grant | $1.7M | Completed | Startup |
JSK Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
JSK Therapeutics Patents
JSK Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3091516-A1 | Composition and method for topical js-k as therapy for actinic keratosis | Inactive | 18-Feb-2018 | ||
| US-20190255040-A1 | Composition and method for topical js-k as therapy for actinic keratosis | Inactive | 18-Feb-2018 | ||
| WO-2019161396-A1 | Composition and method for topical js-k as therapy for actinic keratosis | Inactive | 18-Feb-2018 | A61K31/495 |
JSK Therapeutics Signals
JSK Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cephalon | Corporation | Minority | ||
| Utah Centers of Excellence | Government | |||
| National Cancer Institute | Government | |||
| University of Utah | University | Minority |
JSK Therapeutics FAQs
-
When was JSK Therapeutics founded?
JSK Therapeutics was founded in 2008.
-
Where is JSK Therapeutics headquartered?
JSK Therapeutics is headquartered in Salt Lake City, UT.
-
What is the size of JSK Therapeutics?
JSK Therapeutics has 6 total employees.
-
What industry is JSK Therapeutics in?
JSK Therapeutics’s primary industry is Drug Discovery.
-
Is JSK Therapeutics a private or public company?
JSK Therapeutics is a Private company.
-
What is JSK Therapeutics’s current revenue?
The current revenue for JSK Therapeutics is .
-
How much funding has JSK Therapeutics raised over time?
JSK Therapeutics has raised $6.29M.
-
Who are JSK Therapeutics’s investors?
Cephalon, Utah Centers of Excellence, National Cancer Institute, and University of Utah have invested in JSK Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process